Close Menu

NEW YORK (GenomeWeb) – Grail has raised $900 million out of a planned $1 billion, in the first close a Series B financing round that was led by Arch Venture Partners and included Johnson and Johnson Innovation as well as Amazon, Bristol-Myers Squibb, Celgene, McKesson Ventures, Merck, Tencent Holdings, and Varian Medical Systems. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.